TGFB1 and non-small cell lung carcinoma: 2021). To further explore the impact of lnc‐MMP2‐2 on BM in NSCLC, an in vivo mouse model of BM was established (Wu et al. 2021). The model was created by injecting A549 cells stably transfected with either a control or shlnc‐MMP2‐2 lentivirus, then treated with or without TGF‐β1 (Wu et al. 2021). The results showed that the knockdown of lnc‐MMP2‐2 significantly decreased the incidence of BM, indicating the potential of lnc‐MMP2‐2 as a therapeutic target for NSCLC BM (Wu et al. 2021).